Siwei Biotechnology
PrivateLast Round
Pre-D
May 25, 2023
Est. Valuation
$153M
Total Funding Raised
$239.88M
Company Overview
Siwei Biotechnology is a biotechnology company that develops mRNA-based therapeutics and vaccines for cancer, infectious diseases, and genetic disorders using its proprietary LPP delivery technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Siwei Biotechnology Comparables
Compare Siwei Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enorna Biotechnology | 82% | |
| Zhejiang Innoforce Pharmaceuticals | 80% | |
| Vernal Biosciences | 79% |
Siwei Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre-D | May 25, 2023 | ||||
| Series C | Jun 1, 2021 | ||||
| Series B | Dec 1, 2020 | ||||
| Series A Extension | Feb 1, 2020 | ||||
| Series A | Aug 11, 2019 | ||||
Angel | Jul 1, 2017 |
Siwei Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longmen Capital | Series A |
| Greenwoods Asset Management | Series C |
| 招银国际金融有限公司 | Series C |
| Shanghai Zhangjiang Torch Venture Capital | Series A |
| Triwise Capital | Series A Extension |
| CITIC Group | Series C |
| Qingsong Fund | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 25, 2023
$29M raised in latest financing.
- Jun 1, 2021
$200M round led by Sequoia Capital and China Merchants Health.
Siwei Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Siwei Biotechnology's valuation, stock price, and market status.
Is Siwei Biotechnology a public or private company?
Siwei Biotechnology is a private company.
What is the current stock price of Siwei Biotechnology?
Siwei Biotechnology is a private company with no public stock price. No recent secondary market data is available.
How much is Siwei Biotechnology worth (valuation)?
Siwei Biotechnology's valuation is estimated at $153.0M based on funding round data.
Can I buy Siwei Biotechnology stock?
Siwei Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Siwei Biotechnology's last funding round?
Siwei Biotechnology's most recent funding round was Series D on December 1, 2020.
Who are the main investors in Siwei Biotechnology?
Key investors in Siwei Biotechnology include Longmen Capital, Greenwoods Investments, Sequoia Capital, China Merchants Health, Greenwoods Asset Management.
Will Siwei Biotechnology IPO soon?
No public IPO plans have been announced for Siwei Biotechnology.
How can I track Siwei Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Siwei Biotechnology's secondary market activity and sign up for updates.